文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

AG10稳定转甲状腺素蛋白治疗症状性ATTR心肌病

Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2019-03-15

这项随机双盲安慰剂对照研究评估了AG10在49例症状性ATTR-CM患者中的安全性、耐受性、药代动力学和药效学。结果显示AG10耐受良好,达到目标血浆浓度,并实现TTR的近完全稳定,高剂量组稳定更完全且变异更小。AG10有望成为ATTR-CM的安全有效治疗,3期试验正在进行中。

要点

  • AG10在ATTR-CM患者中耐受良好,达到目标血浆浓度
  • AG10实现TTR近完全稳定,高剂量组更完全且变异更小
  • AG10使所有受试者血清TTR恢复至正常范围

核心结论

  • AG10有望成为ATTR-CM患者安全有效的治疗,3期试验正在进行中。

研究设计与样本

  • 随机、双盲、安慰剂对照研究纳入49例NYHA II-III级症状性ATTR-CM患者(突变型或野生型),按1:1:1随机接受AG10 400 mg、AG10 800 mg或安慰剂每日两次,共28天。
  • 安全性及耐受性通过临床和实验室标准评估,测量AG10血浆水平,通过血清TTR变化及两种体外试验评估TTR稳定性。

主要发现

  • AG10治疗耐受良好,达到目标血浆浓度,并显示TTR近完全稳定。
  • 高剂量组TTR稳定更完全且变异更小,谷浓度时荧光探针排斥法稳定率为92 ± 10%(平均值±标准差),峰浓度时为96 ± 9%(与安慰剂比较均p < 10-12)。
  • 400 mg和800 mg组平均血清TTR分别增加36 ± 21%和51 ± 38%(与安慰剂比较均p < 0.0001)。
  • 治疗前基线血清TTR低于正常者在突变型中占80%,在野生型中占33%。
  • AG10治疗使所有受试者血清TTR恢复至正常范围。

临床怎么用

  • AG10通过稳定TTR发挥作用,可能为ATTR-CM提供口服选择性治疗选择,但需等待3期试验结果确认。

局限性

  • 研究样本量小(n=49),治疗期限短(28天),主要评估安全性和药效学指标,尚未评估临床终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transthyretin (TTR) amyloidosis is an underdiagnosed disease caused by destabilization of TTR due to pathogenic mutations or aging. Both pathogenic and protective mutations illuminate mechanisms of disease and potential interventions. AG10 is a selective, oral TTR stabilizer under development for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that mimics a protective TTR mutation. OBJECTIVES: This randomized, double-blind, placebo-controlled study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of AG10 in ATTR-CM patients with symptomatic, chronic heart failure. METHODS: ATTR-CM, New York Heart Association functional class II to III subjects (n = 49, mutant or wild-type) were randomized 1:1:1 to AG10 400 mg, AG10 800 mg, or placebo twice daily for 28 days. Safety and tolerability were assessed by clinical and laboratory criteria. AG10 plasma levels were measured. TTR stability was assessed by changes in serum TTR, and 2 established ex vivo assays (fluorescent probe exclusion and Western blot). RESULTS: AG10 treatment was well-tolerated, achieved target plasma concentrations and demonstrated near-complete stabilization of TTR. TTR stabilization was more complete and less variable at the higher dose with stabilization by fluorescent probe exclusion of 92 ± 10% (mean ± SD) at trough and 96 ± 9% at peak (both p < 10-12 vs. placebo). Average serum TTR increased by 36 ± 21% and 51 ± 38% at 400 and 800 mg, respectively (both p < 0.0001 vs. placebo). Baseline serum TTR in treated subjects was below normal in 80% of mutant and 33% of wild-type subjects. AG10 treatment restored serum TTR to the normal range in all subjects. CONCLUSIONS: AG10 has the potential to be a safe and effective treatment for patients with ATTR-CM. A phase 3 trial is ongoing. (Study of AG10 in Amyloid Cardiomyopathy; NCT03458130).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Judge DP, Heitner SB, Falk RH, et al. Transthyretin Stabilization by AG10 in Symptomatic Transthyretin Amyloid Cardiomyopathy. J Am Coll Cardiol. 2019. PMID: 30885685. doi:10.1016/j.jacc.2019.03.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。